The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.
On March 17, HSBC analyst Morten Herholdt raised the firm’s price recommendation on Johnson & Johnson (NYSE:JNJ) to $280 from ...
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.
The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's oral pill for psoriasis, the company said.